Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B3US
|
||||
| Former ID |
DNC006570
|
||||
| Drug Name |
Cbz-Ile-MetO2-Ala-LeuVSMe
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C29H46N4O9S2
|
||||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CS(=O)(=O)C)C(=O)NC(C)C(=O)NC(CC(C)C)C=<br />CS(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
|
||||
| InChI |
1S/C29H46N4O9S2/c1-8-20(4)25(33-29(37)42-17-22-12-10-9-11-13-22)28(36)32-24(18-44(7,40)41)27(35)30-21(5)26(34)31-23(16-19(2)3)14-15-43(6,38)39/h9-15,19-21,23-25H,8,16-18H2,1-7H3,(H,30,35)(H,31,34)(H,32,36)(H,33,37)/b15-14+/t20-,21-,23+,24-,25-/m0/s1
|
||||
| InChIKey |
HIMUOMBMABFMIW-VHISICEBSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin S | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | ||||
| Phagosome | |||||
| Antigen processing and presentation | |||||
| Tuberculosis | |||||
| NetPath Pathway | Leptin Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| Reactome | Endosomal/Vacuolar pathway | ||||
| Degradation of the extracellular matrix | |||||
| Trafficking and processing of endosomal TLR | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | ||||
| Trafficking and processing of endosomal TLR | |||||
| References | |||||
| REF 1 | J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.